Moexipril clinical studies

Revision as of 17:50, 14 February 2014 by Amr Marawan (talk | contribs) (Created page with "__NOTOC__ {{Moexipril}} {{CMG}}; {{AE}} {{AM}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE T...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]

Moexipril

Moexipril and Hydrochlorothiazide tablet

Overview

Moexipril tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. hypotension, rash, hyperkalemia, disorder of taste, cough.

Category

Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [4]; Associate Editor(s)-in-Chief: Amr Marawan, M.D. [5]


[1]


References

  1. ↑ "MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLET, COATED [PADDOCK LABORATORIES, INC.]".

Adapted from the FDA Package Insert.

Retrieved from "https://www.wikidoc.org/index.php?title=Moexipril_clinical_studies&oldid=943666"